

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Botulinum Toxins are considered separately in medical policy 00012.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider endoscopic transthoracic sympathectomy (ETS) and surgical excision of axillary sweat glands (applicable only to axillary hyperhidrosis) **eligible for coverage**** for the treatment of primary focal hyperhidrosis (i.e. axillary, palmar, craniofacial regions) when both of the following criteria (1 and 2) are met:

1. Individual has one of the following medical conditions (a-c):
 - a. History of recurrent skin maceration with bacterial or fungal infections; or
 - b. History of recurrent secondary infections; or
 - c. History of persistent eczematous dermatitis despite medical treatments with topical dermatologic or systemic anticholinergic agents; and
2. Individual has failed conservative treatment with aluminum chloride 20% solution and botulinum toxin (applicable only to axillary and palmar hyperhidrosis) used individually and in combination.

Note: Botulinum toxin coverage criteria for axillary and palmar primary hyperhidrosis are noted in MP 00012.

Based on review of available data, the Company considers surgical tympanic neurectomy to be **eligible for coverage**** for the treatment of severe secondary gustatory hyperhidrosis when conservative treatment with aluminum chloride 20% solution has failed.

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers other treatments for focal hyperhidrosis and when coverage criteria are not met to be **investigational***, including but not limited to axillary

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

liposuction, iontophoresis, microwave treatment, radiofrequency ablation, and lumbar sympathectomy for plantar hyperhidrosis.

All other treatments for severe secondary gustatory hyperhidrosis are considered **investigational***, including but not limited to iontophoresis.

Policy Guidelines

Aluminum chloride solution is approved by FDA for treatment of primary hyperhidrosis. At least 1 botulinum toxin product is FDA-approved for treatment in adults of severe axillary hyperhidrosis inadequately managed by topical agents.

Absent evidence to the contrary, botulinum toxin products are considered to have a class effect.

A multispecialty working group have defined primary focal hyperhidrosis as a condition characterized by visible, excessive sweating of at least 6 months in duration without apparent cause and with at least 2 of the following features: bilateral and relatively symmetric sweating, impairment of daily activities, frequency of at least once per week, age at onset younger than 25 years, positive family history, and cessation of focal sweating during sleep.

The Hyperhidrosis Disease Severity Scale is used by patients to rate the severity of their symptoms on a scale of 1 to 4 (see Table PG1):

Table PG1. The Hyperhidrosis Disease Severity Scale

Score	Definition
1	My underarm sweating is never noticeable and never interferes with my daily activities
2	My underarm sweating is tolerable but sometimes interferes with my daily activities
3	My underarm sweating is barely tolerable and frequently interferes with my daily activities
4	My underarm sweating is intolerable and always interferes with my daily activities

Background/Overview

Hyperhidrosis

Hyperhidrosis has been defined as excessive sweating, beyond a level required to maintain normal body temperature, in response to heat exposure or exercise. It can be classified as primary or

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

secondary. Primary focal hyperhidrosis is idiopathic, typically involving the hands (palmar), feet (plantar), or axillae (underarms). Secondary hyperhidrosis can result from a variety of drugs (eg, tricyclic antidepressants, selective serotonin reuptake inhibitors) or underlying diseases/conditions (eg, febrile diseases, diabetes, menopause). Secondary hyperhidrosis is usually generalized or craniofacial sweating.

Secondary gustatory hyperhidrosis is excessive sweating on ingesting highly spiced foods. This trigeminovascular reflex typically occurs symmetrically on the scalp or face and predominately over the forehead, lips, and nose. Secondary facial gustatory occurs independently of the nature of the ingested food. This phenomenon frequently occurs after injury or surgery in the region of the parotid gland. Frey syndrome is an uncommon type of secondary gustatory hyperhidrosis that arises from injury to or surgery near the parotid gland resulting in damage to the secretory parasympathetic fibers of the facial nerve. After the injury, these fibers regenerate, and miscommunication occurs between them and the severed postganglionic sympathetic fibers that supply the cutaneous sweat glands and blood vessels. The aberrant connection results in gustatory sweating and facial flushing with mastication. Aberrant secondary gustatory sweating follows up to 73% of surgical sympathectomies and is particularly common after bilateral procedures.

The consequences of hyperhidrosis are primarily psychosocial. Symptoms such as fever, night sweats, or weight loss require further investigation to rule out secondary causes. Sweat production can be assessed with the Minor starch-iodine test, which is a simple qualitative measure to identify specific sites of involvement.

Treatment

A variety of therapies have been investigated for primary hyperhidrosis, including topical therapy with aluminum chloride, topical anticholinergic medications oral anticholinergic medications, iontophoresis, intradermal injections of botulinum toxin, endoscopic transthoracic sympathectomy, and surgical excision of axillary sweat glands. Treatment of secondary hyperhidrosis focuses on treatment of the underlying cause, such as discontinuing certain drugs or hormone replacement therapy as a treatment for menopausal symptoms.

Iontophoresis uses electrical current to deliver medication transdermally. A charged ionic drug is placed on the skin with an electrode of the same charge, which drives the drug into the skin, with the purpose of achieving better penetration of the drug into underlying tissue. The benefits of this method would be an enhancement of treatment effects and a reduction in adverse events associated with systemic administration of the drug.

Surgical treatment options include removal of the eccrine glands and/or interruption of the sympathetic nerves. Eccrine sweat glands produce an aqueous secretion, the overproduction of which is primarily responsible for hyperhidrosis. These glands are innervated by the sympathetic

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

nervous system. Surgical removal has been performed in patients with severe isolated axillary hyperhidrosis.

Various surgical techniques of sympathectomy have been tested. The second (T2) and third (T3) thoracic ganglia are responsible for palmar hyperhidrosis, the fourth (T4) thoracic ganglion controls axillary hyperhidrosis, and the first (T1) thoracic ganglion controls craniofacial hyperhidrosis. Thoracic sympathectomy has been investigated as a potentially curative procedure, primarily for combined palmar and axillary hyperhidrosis unresponsive to nonsurgical treatments. While accepted as an effective treatment, sympathectomy is not without complications. In addition to the immediate surgical complications of pneumothorax or temporary Horner syndrome, compensatory sweating on the trunk generally occurs in most patients, with different degrees of severity. Medical researchers have investigated whether certain approaches (eg, T3 sympathectomy vs T4 sympathectomy) result in less compensatory sweating, but there remains a lack of consensus about which approach best minimizes the risk of this adverse event. Also, with lumbar sympathectomy for plantar hyperhidrosis, there has been concern about the risk of postoperative sexual dysfunction in both men and women.

Outcome Measures

Outcomes from different surgical and medical treatment modalities are best assessed using a combination of tools. Quantitative tools include gravimetry, evaporimetry, and the Minor starch-iodine test. Qualitative assessment tools include general health surveys and hyperhidrosis-specific surveys. Of these, the Hyperhidrosis Disease Severity Scale has had a good correlation to other assessment tools and is practical in the clinical setting.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 2011, the miraDry[®] System (Miramar Labs) was cleared for marketing by FDA through the 510(k) process for treating primary axillary hyperhidrosis. This microwave device is designed to heat tissue at the dermal-hypodermal interface, the location of the sweat glands. Treatment consists of 2 sessions for a total duration of approximately 1 hour. Sessions occur in a physician's office, and a local anesthetic is used. The device is currently not approved for the treatment of palmar or plantar hyperhidrosis.

In 2023, the Brella[®] Sweat Control Patch (Candesant Biomedical, Inc.) was approved by the FDA through the 513(f)(2) de novo pathway for the treatment of primary axillary hyperhidrosis in adults. The patch is applied by a clinician and kept in place for up to 3 minutes, during which the patch's sodium layer creates heat after coming into contact with sweat, which leads to temporary inactivation of sweat glands.

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Hyperhidrosis, or excessive sweating, can lead to impairments in psychologic and social functioning. Various treatments for hyperhidrosis are available, such as topical antiperspirant agents (eg, aluminum chloride 20% solution), oral medications, botulinum toxin, and surgical procedures.

Primary Focal Hyperhidrosis

Iontophoresis

For individuals who have primary focal hyperhidrosis (ie, axillary, palmar, plantar, craniofacial) who receive iontophoresis, the evidence includes a systematic review, a randomized controlled trial (RCT), and case series. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The RCT found that iontophoresis was less effective than botulinum toxin in the short-term treatment of palmar hyperhidrosis. Additional RCTs are needed comparing iontophoresis with sham or active treatment in patients with various types of primary focal hyperhidrosis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Microwave

For individuals who have primary focal hyperhidrosis (ie, axillary, palmar, plantar, craniofacial) who receive microwave treatment, the evidence includes a systematic review, an RCT, and a case series. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The systematic review and RCT found a short-term benefit of microwave treatment in reducing hyperhidrosis but also reported skin-related adverse events (eg, pain, altered sensation). Additional RCTs are needed comparing microwave treatment with sham or active treatment in patients with various types of primary focal hyperhidrosis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Radiofrequency Ablation

For individuals who have primary focal hyperhidrosis (ie, axillary, palmar, plantar, craniofacial) who receive radiofrequency ablation (RFA), the evidence includes 2 small RCTs and a nonrandomized cohort study. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. One nonrandomized comparative study found RFA inferior to surgical sympathectomy for patients with severe bilateral palmar hyperhidrosis resistant to conservative treatment. Two small RCTs that compared RFA to botulinum toxin A in patients with palmar or axillary hyperhidrosis had conflicting results. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

Surgery

For individuals who have primary axillary hyperhidrosis who receive surgical excision of axillary sweat glands, the evidence includes review articles. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The evidence has shown that excision is highly effective, and this treatment is considered standard of care for this indication. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have primary axillary and palmar hyperhidrosis who receive endoscopic transthoracic sympathectomy, the evidence includes several RCTs, a meta-analysis, and case series. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The meta-analysis found a high rate of clinical efficacy after endoscopic transthoracic sympathectomy, although the rate of postoperative compensatory sweating was substantial. Subsequent studies have supported these findings. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have primary plantar hyperhidrosis who receive lumbar sympathectomy, the evidence includes 1 RCT conducted at a single center in Brazil, case series, and a systematic review. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. Case series have reported high rates of clinical efficacy, but findings are inconclusive due to lack of control groups. The RCT was limited by its small sample size and lack of blinded outcome assessment. Moreover, there have been substantial rates of compensatory sweating and concerns about adverse events on sexual functioning. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Secondary Gustatory Hyperhidrosis

For individuals who have severe secondary gustatory hyperhidrosis who receive iontophoresis or botulinum toxin, the evidence includes uncontrolled studies and systematic reviews. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. The systematic reviews did not identify any relevant RCTs. Randomized controlled trials are needed to evaluate the safety and efficacy of these treatments for severe secondary gustatory hyperhidrosis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have severe secondary gustatory hyperhidrosis who receive tympanic neurectomy, the evidence includes uncontrolled studies and systematic reviews. Relevant outcomes are symptoms, quality of life, and treatment-related morbidity. This treatment has high success rates, without the need for repeated interventions, and is considered standard of care for this indication. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

Supplemental Information

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Institute for Health and Care Excellence

In 2014, NICE issued guidance stating that there was sufficient evidence for the efficacy and safety of endoscopic thoracic sympathectomy for primary facial blushing to support the use of the procedure.

The Institute also issued guidance in 2014 on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. The guidance stated that "current evidence on the efficacy and safety of endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb is adequate to support the use of this procedure." Also: "Due to the risk of side effects, this procedure should only be considered in patients suffering from severe and debilitating primary hyperhidrosis that has been refractory to other treatments."

For severe primary axillary hyperhidrosis, NICE issued guidance in 2017 on the use of transcutaneous microwave ablation. The guidance stated that there is inadequate evidence in both quantity and quality to evaluate the safety and efficacy of microwave ablation.

Society of Thoracic Surgeons

In 2011, the Society of Thoracic Surgeons published an expert consensus statement on the surgical treatment of hyperhidrosis. The document stated that endoscopic thoracic sympathectomy is the treatment of choice for patients with primary hyperhidrosis. It further recommended the following treatment strategies (with R referring to rib and the number to which rib):

- R3 interruption for palmar hyperhidrosis; an R4 interruption is also reasonable. The authors note a slightly higher rate of compensatory sweating with R3, but R3 is also more effective at treating hyperhidrosis.
- R4 or R5 interruption for palmar-axillary, palmar-axillary-plantar, or axillary hyperhidrosis alone; R5 interruption is also an option for axillary hyperhidrosis alone.
- R3 interruption for craniofacial hyperhidrosis without blushing; an R2 and R3 procedure is an option but may lead to a higher rate of compensatory sweating, and also increases the risk of Horner syndrome.

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

According to the statement, endoscopic thoracic sympathectomy has been recommended for patients with severe symptoms that cannot be managed with other therapies who meet the following criteria:

- Onset of hyperhidrosis at an early age (before 16 years)
- <25 years of age at time of surgery
- Body mass index <28 kg/m²
- No sweating during sleep
- No significant comorbidities
- Resting heart rate <55 beats per minute

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Unpublished</i>			
NCT03433859	Prospective Multicentric Open Randomised Controlled Trial Comparing Topical Aluminium Chloride to OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)	54	Mar 2021
NCT02854540	Management of Palmar Hyperhidrosis with Hydrogel-based Iontophoresis	13	Aug 2018
NCT03236012	Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Treatment Approach	25	Feb 2022
NCT05057117	Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis: a Randomized Intra-Individual Trial	30	Apr 2023
<i>Ongoing</i>			

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

NCT02295891	Microwave Energy-induced Thermolysis of Axillary Apocrine Glands and Hair Follicles Will Result in Improvement of Secondary Psychopathology Related to Hyperhidrosis	24	Nov 2024
NCT03921320	Evaluation of Compensatory Sweating After Unilateral Videothoroscopic Sympathectomy of the Dominant Side or Sequential Bilateral Videothoroscopic Sympathectomy: a Multicentric Randomized Trial	200	Dec 2023 (status unknown)
NCT05737914	Bilateral Endoscopic Thoracic T3 Sympathectomy Versus T3 Radiofrequency Ablation for Treatment of Primary Palmar Hyperhidrosis	68	Oct 2023 (status unknown)

NCT: national clinical trial.

References

1. Food and Drug Administration. Approved risk evaluation and mitigation strategies. <https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm>.
2. Wade R, Rice S, Llewellyn A, et al. Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis. *Health Technol Assess*. Dec 2017; 21(80): 1-280. PMID 29271741
3. Rajagopal R, Mallya NB. Comparative evaluation of botulinum toxin versus iontophoresis with topical aluminium chloride hexahydrate in treatment of palmar hyperhidrosis. *Med J Armed Forces India*. Jul 2014; 70(3): 247-52. PMID 25378778
4. Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. *Dermatol Surg*. Aug 2007; 33(8): 908-23. PMID 17661933
5. Dogruk Kacar S, Ozuguz P, Eroglu S, et al. Treatment of primary hyperhidrosis with tap water iontophoresis in pediatric patients: a retrospective analysis. *Cutan Ocul Toxicol*. Dec 2014; 33(4): 313-6. PMID 24405389
6. McAleer MA, Collins P. A study investigating patients' experience of hospital and home iontophoresis for hyperhidrosis. *J Dermatolog Treat*. Aug 2014; 25(4): 342-4. PMID 23356798
7. Obed D, Salim M, Bingoel AS, et al. Botulinum Toxin Versus Placebo: A Meta-Analysis of Treatment and Quality-of-life Outcomes for Hyperhidrosis. *Aesthetic Plast Surg*. Aug 2021; 45(4): 1783-1791. PMID 33619611
8. Lowe NJ, Glaser DA, Eadie N, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. *J Am Acad Dermatol*. Apr 2007; 56(4): 604-11. PMID 17306417

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

9. Baumann L, Slezinger A, Halem M, et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis. *Int J Dermatol*. May 2005; 44(5): 418-24. PMID 15869543
10. Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. *J Neural Transm (Vienna)*. Mar 2010; 117(3): 317-9. PMID 20143241
11. Talarico-Filho S, Mendonça DO Nascimento M, Sperandeo DE Macedo F, et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. *Dermatol Surg*. Jan 2007; 33(1 Spec No.): S44-50. PMID 17241414
12. Frasson E, Brigo F, Acler M, et al. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months. *Arch Dermatol*. Jan 2011; 147(1): 122-3. PMID 21242408
13. An JS, Hyun Won C, Si Han J, et al. Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis. *Dermatol Surg*. Aug 2015; 41(8): 960-7. PMID 26218729
14. Grove GL, Togsverd-Bo K, Zachariae C, et al. Botulinum toxin A versus microwave thermolysis for primary axillary hyperhidrosis: A randomized controlled trial. *JAAD Int*. Jun 2024; 15: 91-99. PMID 38495540
15. Mirkovic SE, Rystedt A, Balling M, et al. Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin. *Acta Derm Venereol*. Jan 12 2018; 98(1): 103-107. PMID 28761964
16. Lowe NJ, Yamauchi PS, Lask GP, et al. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. *Dermatol Surg*. Sep 2002; 28(9): 822-7. PMID 12269876
17. Saadia D, Voustianiouk A, Wang AK, et al. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. *Neurology*. Dec 11 2001; 57(11): 2095-9. PMID 11739832
18. Campanati A, Giuliadori K, Martina E, et al. Onabotulinumtoxin type A (Botox(®)) versus Incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. *J Neural Transm (Vienna)*. Jan 2014; 121(1): 21-6. PMID 24052109
19. Baumann L, Slezinger A, Halem M, et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. *Dermatol Surg*. Mar 2005; 31(3): 263-70. PMID 15841624
20. Hsu TH, Chen YT, Tu YK, et al. A systematic review of microwave-based therapy for axillary hyperhidrosis. *J Cosmet Laser Ther*. Oct 2017; 19(5): 275-282. PMID 28281850
21. Glaser DA, Coleman WP, Fan LK, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. *Dermatol Surg*. Feb 2012; 38(2): 185-91. PMID 22289389
22. Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. *Dermatol Surg*. May 2012; 38(5): 728-35. PMID 22452511

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

23. Mostafa TAH, Hamed AA, Mohammed BM, et al. C-Arm Guided Percutaneous Radiofrequency Thoracic Sympathectomy for Treatment of Primary Palmar Hyperhidrosis in Comparison with Local Botulinum Toxin Type A Injection, Randomized Trial. *Pain Physician*. Nov 2019; 22(6): 591-599. PMID 31775406
24. Rummaneethorn P, Chalermchai T. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis. *Lasers Med Sci*. Jul 2020; 35(5): 1179-1184. PMID 31939036
25. Zhong Y, Zhu Y, Li J, et al. Efficacy and safety of radiofrequency ablation versus surgical sympathectomy in palmar hyperhidrosis. *Sci Rep*. Apr 01 2024; 14(1): 7620. PMID 38556580
26. Purtuloglu T, Atim A, Deniz S, et al. Effect of radiofrequency ablation and comparison with surgical sympathectomy in palmar hyperhidrosis. *Eur J Cardiothorac Surg*. Jun 2013; 43(6): e151-4. PMID 23428574
27. Hafner J, Beer GM. Axillary sweat gland excision. *Curr Probl Dermatol*. 2002; 30: 57-63. PMID 12471699
28. Deng B, Tan QY, Jiang YG, et al. Optimization of sympathectomy to treat palmar hyperhidrosis: the systematic review and meta-analysis of studies published during the past decade. *Surg Endosc*. Jun 2011; 25(6): 1893-901. PMID 21136103
29. Baumgartner FJ, Reyes M, Sarkisyan GG, et al. Thoracoscopic sympathectomy for disabling palmar hyperhidrosis: a prospective randomized comparison between two levels. *Ann Thorac Surg*. Dec 2011; 92(6): 2015-9. PMID 22115211
30. Yuncu G, Turk F, Ozturk G, et al. Comparison of only T3 and T3-T4 sympathectomy for axillary hyperhidrosis regarding treatment effect and compensatory sweating. *Interact Cardiovasc Thorac Surg*. Aug 2013; 17(2): 263-7. PMID 23644731
31. de Andrade Filho LO, Kuzniec S, Wolosker N, et al. Technical difficulties and complications of sympathectomy in the treatment of hyperhidrosis: an analysis of 1731 cases. *Ann Vasc Surg*. May 2013; 27(4): 447-53. PMID 23406790
32. Karamustafaoglu YA, Kuzucuoglu M, Yanik F, et al. 3-year follow-up after uniportal thoracoscopic sympathectomy for hyperhidrosis: undesirable side effects. *J Laparoendosc Adv Surg Tech A*. Nov 2014; 24(11): 782-5. PMID 25376004
33. Smidfelt K, Drott C. Late results of endoscopic thoracic sympathectomy for hyperhidrosis and facial blushing. *Br J Surg*. Dec 2011; 98(12): 1719-24. PMID 21928403
34. Wait SD, Killory BD, Lekovic GP, et al. Thoracoscopic sympathectomy for hyperhidrosis: analysis of 642 procedures with special attention to Horner's syndrome and compensatory hyperhidrosis. *Neurosurgery*. Sep 2010; 67(3): 652-6; discussion 656-7. PMID 20647968
35. Lembrana L, Wolosker N, de Campos JRM, et al. Videothoracoscopic Sympathectomy Results after Oxybutynin Chloride Treatment Failure. *Ann Vasc Surg*. Aug 2017; 43: 283-287. PMID 28478174
36. de Campos JRM, Lembrana L, Fukuda JM, et al. Evaluation of patients who underwent resympathectomy for treatment of primary hyperhidrosis. *Interact Cardiovasc Thorac Surg*. Nov 01 2017; 25(5): 716-719. PMID 29049566

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

37. Fukuda JM, Varella AYM, Teivelis MP, et al. Video-Assisted Thoracoscopic Sympathectomy for Facial Hyperhidrosis: The Influence of the Main Site of Complaint. *Ann Vasc Surg.* Jan 2018; 46: 337-344. PMID 28689957
38. Vasconcelos-Castro S, Soares-Oliveira M, Tuna T, et al. Thoracoscopic sympathectomy for palmar hyperhidrosis: How young is too young?. *J Pediatr Surg.* Nov 2020; 55(11): 2362-2365. PMID 31870560
39. Lima SO, Santos RS, Moura AMM, et al. A systematic review and meta-analysis to evaluate the efficacy of lumbar sympathectomy for plantar hyperhidrosis. *Int J Dermatol.* Aug 2019; 58(8): 982-986. PMID 31099425
40. Loureiro Mde P, de Campos JR, Kauffman P, et al. Endoscopic lumbar sympathectomy for women: effect on compensatory sweat. *Clinics (Sao Paulo).* Apr 2008; 63(2): 189-96. PMID 18438572
41. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. *J Am Acad Dermatol.* Aug 2004; 51(2): 274-86. PMID 15280848
42. Li C, Wu F, Zhang Q, et al. Interventions for the treatment of Frey's syndrome. *Cochrane Database Syst Rev.* Mar 17 2015; 2015(3): CD009959. PMID 25781421
43. Clayman MA, Clayman SM, Seagle MB. A review of the surgical and medical treatment of Frey syndrome. *Ann Plast Surg.* Nov 2006; 57(5): 581-4. PMID 17060744
44. de Bree R, van der Waal I, Leemans CR. Management of Frey syndrome. *Head Neck.* Aug 2007; 29(8): 773-8. PMID 17230557
45. Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology.* May 06 2008; 70(19): 1707-14. PMID 18458231
46. Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. *Toxicon.* Jun 01 2013; 67: 141-52. PMID 23178324
47. National Institute of Health and Care Excellence (NICE). Endoscopic thoracic sympathectomy for primary facial blushing [IPG480]. 2014; <https://www.nice.org.uk/guidance/ipg480>.
48. National Institute of Health and Care Excellence (NICE). Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb [IPG487]. 2014; <https://www.nice.org.uk/guidance/ipg487>.
49. National Institute of Health and Care Excellence (NICE). Transcutaneous microwave ablation for severe primary axillary hyperhidrosis [IPG601]. 2017; <https://www.nice.org.uk/guidance/ipg601>.
50. Cerfolio RJ, De Campos JR, Bryant AS, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. *Ann Thorac Surg.* May 2011; 91(5): 1642-8. PMID 21524489

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

Policy History

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

06/07/2005	Medical Director review
06/21/2005	Medical Policy Committee review
07/15/2005	Managed Care Advisory Council approval
07/12/2006	Medical Director review
07/19/2006	Medical Policy Committee review. Format revisions. FDA information added. No change in policy statement.
08/01/2007	Medical Director review
08/15/2007	Medical Policy Committee approval. No change to coverage eligibility.
08/06/2008	Medical Director review
08/20/2008	Medical Policy Committee approval. Updated rationale. No change to coverage eligibility.
08/06/2009	Medical Policy Committee approval
08/26/2009	Medical Policy Implementation Committee approval. No change to coverage eligibility.
11/12/2009	Medical Policy Committee approval.
11/18/2009	Medical Policy Implementation Committee approval. Deleted the “When Services Are Considered Not Medically Necessary” section. Added that when patient selection criteria are not met, to deny investigational.
11/04/2010	Medical Policy Committee review
11/16/2010	Medical Policy Implementation Committee approval. Added to the coverage section <i>Note that <u>incobotulinumtoxinA (Xeomin®)</u> ‡ is not indicated for hyperhidrosis.</i> Coverage eligibility unchanged.
11/03/2011	Medical Policy Committee review
11/16/2011	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/01/2012	Medical Policy Committee review
11/28/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
04/01/2013	Coding updated
06/04/2013	Criteria clarified. Changed from “any” to “both”.
08/01/2013	Medical Policy Committee review
08/21/2013	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/06/2014	Medical Policy Committee review
03/19/2014	Medical Policy Implementation Committee approval. Changed “Botox” to botulinum toxin type A products to coincide with the updates to the Botox policy. Also added a statement reflecting use of botulinum toxin type B to be investigational for primary hyperhidrosis.
06/04/2015	Medical Policy Committee review
06/20/2015	Medical Policy Implementation Committee approval. No change to coverage.

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
06/02/2016	Medical Policy Committee review
06/20/2016	Medical Policy Implementation Committee approval. No change to coverage.
06/01/2017	Medical Policy Committee review
06/21/2017	Medical Policy Implementation Committee approval. Revised the eligible for coverage statement by removing “the use of aluminum chloride, botulinum toxin type A products (Botox, Xeomin, Dysport)”. Revised the first criteria bullet to state “Medical complications such as persistent skin maceration with recurrent secondary infections or persistent eczematous dermatitis despite medical treatments with topical dermatologic agents.” Removed the second investigational statement regarding the treatment of primary hyperhidrosis with botulinum toxin type B (Myobloc). Added “microwave treatment, radiofrequency ablation, lumbar sympathectomy” to investigational statement.
06/07/2018	Medical Policy Committee review
06/20/2018	Medical Policy Implementation Committee approval. No change to coverage.
06/06/2019	Medical Policy Committee review
06/19/2019	Medical Policy Implementation Committee approval. No change to coverage.
09/03/2020	Medical Policy Committee review
09/09/2020	Medical Policy Implementation Committee approval. Botox products removed from this policy.
09/02/2021	Medical Policy Committee review
09/08/2021	Medical Policy Implementation Committee approval. No change to coverage.
09/01/2022	Medical Policy Committee review
09/14/2022	Medical Policy Implementation Committee approval. Removed the When Services are considered Not Medically Necessary section from policy. Coding Update
09/07/2023	Medical Policy Committee review
09/13/2023	Medical Policy Implementation Committee approval. No change to coverage.
09/05/2024	Medical Policy Committee review
09/11/2024	Medical Policy Implementation Committee approval. No change to coverage.
09/04/2025	Medical Policy Committee review
09/10/2025	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 09/2026

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2024 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character*

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	11450, 11451, 15839, 32664, 64650, 64653, 64818, 69676
HCPCS	No codes
ICD-10 Diagnosis	L74.510-L74.519, L74.52, R61

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);

Treatment of Hyperhidrosis

Policy # 00172

Original Effective Date: 07/15/2005

Current Effective Date: 10/01/2025

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.